These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 1655448)

  • 1. Treatment of experimental murine Coxsackie B3 myocarditis.
    Herzum M; Huber SA; Weller R; Grebe R; Maisch B
    Eur Heart J; 1991 Aug; 12 Suppl D():200-2. PubMed ID: 1655448
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytokine and murine coxsackievirus B3 myocarditis. Interleukin-2 suppressed myocarditis in the acute stage but enhanced the condition in the subsequent stage.
    Kishimoto C; Kuroki Y; Hiraoka Y; Ochiai H; Kurokawa M; Sasayama S
    Circulation; 1994 Jun; 89(6):2836-42. PubMed ID: 8205699
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of FK 506 on myocarditis in the enteroviral murine model.
    McManus BM; Han L; Caruso R; Stratta RJ; Wilson JE
    Transplant Proc; 1991 Dec; 23(6):3365-7. PubMed ID: 1721463
    [No Abstract]   [Full Text] [Related]  

  • 4. Effects of in vivo administration of anti-B7-1/B7-2 monoclonal antibodies on the survival of mice with chronic ongoing myocarditis caused by Coxsackievirus B3.
    Seko Y; Takahashi N; Yagita H; Okumura K; Azuma M; Yazaki Y
    J Pathol; 1999 May; 188(1):107-12. PubMed ID: 10398149
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Coxsackievirus B3 murine myocarditis: a pathologic spectrum of myocarditis in genetically defined inbred strains.
    Herskowitz A; Wolfgram LJ; Rose NR; Beisel KW
    J Am Coll Cardiol; 1987 Jun; 9(6):1311-9. PubMed ID: 3034991
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Monoclonal antibody therapy for prevention of acute coxsackievirus B3 myocarditis in mice.
    Kishimoto C; Abelmann WH
    Circulation; 1989 Jun; 79(6):1300-8. PubMed ID: 2541943
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunosuppression with high doses of cyclophosphamide reduces the severity of myocarditis but increases the mortality in murine Coxsackievirus B3 myocarditis.
    Kishimoto C; Thorp KA; Abelmann WH
    Circulation; 1990 Sep; 82(3):982-9. PubMed ID: 2168299
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Coxsackie B3 myocarditis in athymic mice.
    Robinson JA; O'Connell JB; Roeges LM; Major EO; Gunnar RM
    Proc Soc Exp Biol Med; 1981 Jan; 166(1):80-91. PubMed ID: 6258175
    [No Abstract]   [Full Text] [Related]  

  • 9. High yield production of an inactivated coxsackie B3 adjuvant vaccine with protective effect against experimental myocarditis.
    Fohlman J; Pauksen K; Morein B; Bjare U; Ilbäck NG; Friman G
    Scand J Infect Dis Suppl; 1993; 88():103-8. PubMed ID: 8390713
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of verapamil on acute coxsackievirus B3 murine myocarditis.
    Xu Y; Yang YZ; Chen HZ; Jin PY; Guo Q; Zhao WZ; Yang JH; Cai QX; Zhou YC
    Chin Med J (Engl); 1992 Oct; 105(10):818-21. PubMed ID: 1337875
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CTLA4-Ig relieves inflammation in murine models of coxsackievirus B3-induced myocarditis.
    Han B; Jiang H; Liu Z; Zhang Y; Zhao L; Lu K; Xi J
    Can J Cardiol; 2012; 28(2):239-44. PubMed ID: 22336520
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recombinant coxsackievirus vectors for prevention and therapy of virus-induced heart disease.
    Henke A; Jarasch N; Martin U; Wegert J; Wildner A; Zell R; Wutzler P
    Int J Med Microbiol; 2008 Jan; 298(1-2):127-34. PubMed ID: 17897883
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effects of FK-506, a novel and potent immunosuppressant, upon murine Coxsackievirus B3 myocarditis.
    Hiraoka Y; Kishimoto C; Kurokawa M; Ochiai H; Sasayama S
    J Pharmacol Exp Ther; 1992 Mar; 260(3):1386-91. PubMed ID: 1372051
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetics of Coxsackie B3 (CVB3) myocarditis.
    Van Houten N; Huber SA
    Eur Heart J; 1991 Aug; 12 Suppl D():108-12. PubMed ID: 1655440
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of a murine model of myocarditis induced by a reactivated coxsackievirus B3.
    Zhang H; Yousef GE; Ouyang X; Archard LC
    Int J Exp Pathol; 1994 Apr; 75(2):99-110. PubMed ID: 8199011
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Failure of treatment with interleukin-2 receptor-specific monoclonal antibody in acute coxsackievirus B3 myocarditis in mice.
    Kishimoto C; Hiraoka Y; Takada H; Kurokawa M; Ochiai H
    Heart Vessels; 1997; 12(5):221-8. PubMed ID: 9846807
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [An experimental study of the effect of Radix astragali on mice with viral myocarditis infected by Coxsackie B-3].
    Yang Y
    Zhonghua Xin Xue Guan Bing Za Zhi; 1991 Jun; 19(3):186-8. PubMed ID: 1655376
    [No Abstract]   [Full Text] [Related]  

  • 18. Murine natural killer cells limit coxsackievirus B3 replication.
    Godeny EK; Gauntt CJ
    J Immunol; 1987 Aug; 139(3):913-8. PubMed ID: 3036947
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Coronary microvascular narrowing in acute murine coxsackie B3 myocarditis.
    Silver MA; Kowalczyk D
    Am Heart J; 1989 Jul; 118(1):173-4. PubMed ID: 2545091
    [No Abstract]   [Full Text] [Related]  

  • 20. Intricacies of cardiac damage in coxsackievirus B3 infection: implications for therapy.
    Massilamany C; Gangaplara A; Reddy J
    Int J Cardiol; 2014 Dec; 177(2):330-339. PubMed ID: 25449464
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.